Eledon Pharmaceuticals Inc
NASDAQ:ELDN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.12
5.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc
Accrued Liabilities
Eledon Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
Accrued Liabilities
$6.6m
|
CAGR 3-Years
40%
|
CAGR 5-Years
36%
|
CAGR 10-Years
10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
Eledon Pharmaceuticals Inc
Glance View
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).
See Also
What is Eledon Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
6.6m
USD
Based on the financial report for Sep 30, 2024, Eledon Pharmaceuticals Inc's Accrued Liabilities amounts to 6.6m USD.
What is Eledon Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
10%
Over the last year, the Accrued Liabilities growth was 176%. The average annual Accrued Liabilities growth rates for Eledon Pharmaceuticals Inc have been 40% over the past three years , 36% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
